Skip to main content

Medulloblastoma

2
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Sandoz
SandozAustria - Kundl
2 programs
1
1
LDE225Phase 21 trial
LDE225Phase 1/21 trial
Active Trials
NCT01125800Completed76Est. Oct 2014
NCT01708174Completed22Est. Oct 2016
Novartis
NovartisBASEL, Switzerland
1 program
LDE225PHASE_1_2
Genentech
GenentechCA - Oceanside
1 program
Craniospinal Irradiation with boost to the primary tumor sitePHASE_21 trial
Active Trials
NCT01878617Active Not Recruiting660Est. Oct 2031

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
GenentechCraniospinal Irradiation with boost to the primary tumor site
SandozLDE225
SandozLDE225

Clinical Trials (3)

Total enrollment: 758 patients across 3 trials

NCT01878617GenentechCraniospinal Irradiation with boost to the primary tumor site

A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

Start: Jun 2013Est. completion: Oct 2031660 patients
Phase 2Active Not Recruiting
NCT01708174SandozLDE225

A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB)

Start: May 2013Est. completion: Oct 201622 patients
Phase 2Completed
NCT01125800SandozLDE225

A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB

Start: Feb 2011Est. completion: Oct 201476 patients
Phase 1/2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.